Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: Molluscum Contagiosum
Interventions: VBP-245 Topical Gel, Vehicle; Drug
Lead sponsor: Veloce BioPharma LLC; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Fort Washington, Pennsylvania • Greenville, South Carolina • Mt. Pleasant, South Carolina

Conditions: Respiratory Syncytial Virus Infections
Interventions: Placebo, Active; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 1 Day to 60 Months
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 3
States / cities: Los Angeles, California • St Louis, Missouri

Conditions: Paramyxoviridae Infections, Virus Diseases
Interventions: rHPIV3cp45, rHPIV3cp45 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 36 Months
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Seattle, Washington

Conditions: HIV Infections, AIDS
Interventions: raltegravir, efavirenz; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 50 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Sacramento, California

Conditions: T-cell Lymphoma, B-Cell Lymphoma, ATL, Myeloma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hiv, Cigarette Smoking
Interventions: Computer delivered smoking cessation counseling; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Non-infectious Intermediate and Posterior Uveitis
Interventions: Methotrexate; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Atazanavir, Nelfinavir mesylate, Stavudine, Didanosine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 16
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 10 more

Conditions: HIV/AIDS
Interventions: bictegravir/emtricitabine/tenofovir alafenamide; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 411 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
Interventions: TNX-102 SL, Placebo SL Tablet; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 29
States / cities: Birmingham, Alabama • Oceanside, California • Santa Ana, California + 25 more

Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Interventions: Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo; Biological · Drug
Lead sponsor: Beijing Luzhu Biotechnology Co., Ltd.; Other
Eligibility: 50 Years to 70 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: HIV-1-infection
Interventions: GS-1219, BVY, Standard of Care; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 9 more

Conditions: AIDS
Interventions: GSK Biologicals HIV Vaccine 732462, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 191 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 17
States / cities: Bakersfield, California • Long Beach, California • Washington D.C., District of Columbia + 13 more

Conditions: Hidradenitis Suppurativa
Interventions: Tulisokibart, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 16 more

Conditions: Hidradenitis Suppurativa
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: Not listed
Enrollment: 175 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2030
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, HIV (Human Immunodeficiency Virus)
Interventions: Resmetirom, Placebo Control; Drug
Lead sponsor: Naga P. Chalasani; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • La Jolla, California • San Francisco, California + 7 more

Conditions: Diabetes, Wound Infection, Healthy Volunteers
Interventions: Ceftolozane/tazobactam, Microdialysis Catheter Insertion; Drug · Procedure
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Interventions: Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing); Biological
Lead sponsor: Sarang K. Yoon, DO, MOH; Other
Eligibility: 18 Years and older
Enrollment: 1,188 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Community-acquired Infection
Interventions: GSK2251052; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Microtia, Dysbiosis, Alcohol Drinking, HIV Infections, Cardiovascular Diseases
Interventions: Probiotic, Placebo; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HIV Infection
Interventions: Nutropin, Oral Glucose Tolerance Test, Dual Energy X-ray Absorptiometry (DEXA), Computed Tomography (CT) Scan; Drug · Procedure
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 3
States / cities: Dallas, Texas

Conditions: HIV-1-infection
Interventions: Bictegravir/emtricitabine/tenofovir alafenamide; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Methicillin-Resistant Staphylococcus Aureus, Atopic Dermatitis, Eczema Herpeticum, MRSA
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Year to 80 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: San Diego, California • Denver, Colorado

Conditions: HIV/AIDS, Gonorrhea, Chlamydia
Interventions: Keep It Up! 3.0; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 34 Years · Male only
Enrollment: 2,249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and Children

Pilot Project of Virologic and Immunologic Correlates of GALT Immune Reconstitution Following Raltegravir Therapy

Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer

Cultural Adaptation and Piloting of a Smoking Cessation Intervention for Smokers With HIV

Treatment of Non-infectious Intermediate and Posterior Uveitis Associated Macular Edema With Intravitreal Methotrexate

Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

Study of GS-1219 in Participants With HIV-1

Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons

Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)

The Ohio State University Dermatology Biorepository

A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Tissue Penetration of Ceftolozane/Tazobactam in Diabetic Patients With Lower Limb Infections

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

An Open-label, Randomized, Single Period, Parallel-Cohort Study To Evaluate Serum and Pulmonary Pharmacokinetics Following Single and Multiple Dose Administration of Intravenous GSK2251052 in Healthy Adult Subjects

Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

The Use of Nutropin Depot in HIV-infected Adult Males

Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE

The Underlying Mechanisms For S. Aureus Infection And Colonization Of Skin in People With Atopic Dermatitis With And Without Eczema Herpeticum (MRSA)

A Pragmatic Trial of Two Strategies for Implementing an Effective eHealth HIV Prevention Program (Keep It Up! 3.0)